| Autor: |
Mavroudis, D., Bolonakis, I., Cornet, S., Myllaki, G., Kanellou, P., Kotsakis, A., Galanis, A., Nikoloudi, I., Spyropoulou, M., Menez, J., Miconnet, I., Niniraki, M., Cordopatis, P., Kosmatopoulos, K., Georgoulias, V. |
| Předmět: |
|
| Zdroj: |
Oncology; 2006, Vol. 70 Issue 4, p306-314, 9p, 3 Charts, 1 Graph |
| Abstrakt: |
Objective: It was the aim of this study to evaluate the safety of the optimized cryptic peptide TERT572Y in pretreated patients with advanced cancer. Methods: Nineteen patients with progressive and chemotherapy-refractory tumors received escalated doses (2–6 mg) of 2 subcutaneous injections of the optimized TERT572Y peptide followed by 4 subcutaneous injections of the native TERT572 peptide every 3 weeks. Both TERT peptides were coinjected with adjuvant Montanide ISA51. Toxicity was evaluated every 3 weeks and peptide-specific CD8+ cells were detected by flow cytometry using TERT572Y tetramers. Results: Fourteen out of 19 patients completed the vaccination program. No grade III/IV toxicity was observed. Grade I anemia was observed in 4 patients and local skin reaction at the injection site in 11 patients. Other nonhematologic toxicities were mild, and no late toxicity was observed after a median postvaccination follow-up period of 10.7 months. There was no dose-limiting toxicity. Peripheral blood TERT572Y-specific CD8+ lymphocytes were detected in 13 out of 14 evaluable patients after 2 injections with the optimized TERT572Y peptide. There was no complete or partial response, but 4 patients (21%) with persistent TERT572Y-specific CD8+ experienced stable disease for a median of 10.5 months. Conclusion: TERT572Y peptide vaccine is well tolerated and effective in eliciting specific TERT572Y CD8+ lymphocytes in pretreated cancer patients, demonstrating that cryptic peptides could be used in cancer immunotherapy. Copyright © 2006 S. Karger AG, Basel [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
